NCT06195137View on ClinicalTrials.gov

Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)

NACompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

June 15, 2023

Study Completion Date

June 23, 2023

Conditions
CaffeineBurning Mouth Syndrome
Interventions
DIETARY_SUPPLEMENT

Caffeine

caffeine supplementation

DRUG

Alpha Lipoic Acid

600-800 mg ALA

Trial Locations (1)

610041

West China Hospital of Stomatology, Sichuan University, Chengdu

All Listed Sponsors
lead

Lu Jiang

OTHER

NCT06195137 - Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.) | Biotech Hunter | Biotech Hunter